Chen H.-Y.Liu C.-H.Chang Y.-H.SUNG-LIANG YUHo B.C.Hsu C.-P.Yang T.-Y.Chen K.-C.Hsu K.-H.Tseng J.-S.Hsia J.-Y.Chuang C.-Y.Chang C.-S.Li Y.-C.Li K.-C.Chang G.-C.PAN-CHYR YANG2020-12-022020-12-0220161949-2553https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961602243&doi=10.18632%2foncotarget.7029&partnerID=40&md5=e074641c58ac4da72a8493a7e3233814https://scholars.lib.ntu.edu.tw/handle/123456789/523496In this study, EGFR-activating mutation status and DNA copy number abundances of members of ErbB family were measured in 261 lung adenocarcinomas. The associations between DNA copy number abundances of ErbB family, EGFR-activating mutation status, and prognosis were explored. Results showed that DNA copy number abundances of EGFR, ERBB2, ERBB3, and ERBB4 had associations with overall survival in lung adenocarcinoma with EGFR-activating mutations. In the stratification analysis, only ERBB2 showed significant discrepancy in patients carrying wild type EGFR and other members of ErbB family in patients carrying EGFR-activating mutation. This indicated that CNAs of ErbB family had effect modifications of EGFR-activating mutation status. Findings of this study demonstrate potential molecular guidance of patient management of lung adenocarcinoma with or without EGFR-activating mutations.[SDGs]SDG3epidermal growth factor receptor; epidermal growth factor receptor 2; epidermal growth factor receptor 3; epidermal growth factor receptor 4; EGFR protein, human; epidermal growth factor receptor; epidermal growth factor receptor 2; epidermal growth factor receptor 3; epidermal growth factor receptor 4; ERBB2 protein, human; ERBB3 protein, human; ERBB4 protein, human; Article; cancer prognosis; cancer survival; controlled study; disease association; exon; female; gene deletion; gene dosage; gene mutation; genetic association; human; human tissue; lung adenocarcinoma; male; mutational analysis; overall survival; survival prediction; wild type; adenocarcinoma; enzyme activation; gene dosage; genetics; lung tumor; metabolism; mortality; pathology; Adenocarcinoma; Enzyme Activation; Female; Gene Dosage; Humans; Lung Neoplasms; Male; Receptor, Epidermal Growth Factor; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4journal article10.18632/oncotarget.7029268249842-s2.0-84961602243